Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

Type
Public
HQ
Redwood City, US
Founded
2010
Size (employees)
127 (est)-3%
Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US
Report incorrect company information

Coherus BioSciences Office Locations

Coherus BioSciences has an office in Redwood City
Redwood City, US (HQ)
600 333 Twin Dolphin Dr
Show all (1)
Report incorrect company information

Coherus BioSciences Financials and Metrics

Coherus BioSciences Financials

Coherus BioSciences's revenue was reported to be $1.56 m in FY, 2017
USD

Revenue (FY, 2017)

1.6 m

Net income (FY, 2017)

(238.3 m)

EBIT (FY, 2017)

(232.1 m)

Market capitalization (20-Apr-2018)

633.1 m

Cash (31-Dec-2017)

126.9 m
Coherus BioSciences's current market capitalization is $633.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

31.1 m30 m190.1 m1.6 m

Revenue growth, %

(3%)533%

General and administrative expense

17.6 m36 m51.6 m71.3 m

R&D expense

78.2 m213.1 m254.4 m162.4 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

12.4 m14.1 m

General and administrative expense

4 m6.1 m8.8 m10.2 m11.4 m11.3 m13.6 m18.8 m23.5 m

R&D expense

18.5 m36.5 m56.9 m68.2 m65.3 m65.5 m64.6 m53.8 m34.5 m

Operating expense total

22.5 m42.6 m65.8 m78.4 m76.7 m76.8 m78.2 m72.6 m58 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

150.4 m158.2 m124.9 m126.9 m

Inventories

1.9 m

Current Assets

179.1 m197.4 m161.5 m145.5 m

PP&E

4.5 m10.5 m10.8 m12.8 m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

100.9 m115.1 m206.1 m153.7 m179.6 m220.9 m159.7 m124.9 m73.4 m

Current Assets

118.9 m143.9 m239.6 m189.3 m211.6 m236.8 m177.3 m208.3 m153.3 m

PP&E

3.7 m5.1 m6.3 m8.7 m10.3 m9.9 m10.7 m14.9 m14.5 m

Goodwill

943 k943 k943 k943 k943 k943 k943 k943 k943 k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(87.2 m)(223.9 m)(127.8 m)(238.3 m)

Depreciation and Amortization

674 k3 m3.4 m

Accounts Payable

3.6 m(5 m)(3.8 m)

Cash From Operating Activities

(23.9 m)(252.5 m)(200.3 m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(7.9 m)(40.8 m)(99.9 m)(171.4 m)(65.5 m)(135.7 m)(51.8 m)(74.8 m)(130.2 m)

Depreciation and Amortization

632 k1.3 m717 k1.4 m2.2 m865 k1.7 m

Accounts Payable

4.4 m10.9 m7.1 m19.1 m(6.8 m)(7.4 m)(1.6 m)(7.3 m)(3.8 m)

Cash From Operating Activities

(53.9 m)(113.6 m)(76.3 m)(103.7 m)(165.7 m)(73.3 m)(128.9 m)
USDY, 2017

Revenue/Employee

10.6 k

Financial Leverage

5.3 x
Show all financial metrics
Report incorrect company information